香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年年度報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年3 月2 4 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 * 僅供識別 上海复星 ...

Core Viewpoint - Southbound funds reduced their holdings in Fosun Pharma (02196.HK) by 52,000 shares on February 26, while net purchases occurred on 3 out of the last 5 trading days, totaling 514,000 shares [1] Group 1: Southbound Fund Activity - Over the last 20 trading days, Fosun Pharma experienced net purchases from southbound funds on 11 days, accumulating a total of 229,500 shares [1] - Currently, southbound funds hold 319 million shares of Fosun Pharma, representing 57.76% of the company's total issued ordinary shares [1] Group 2: Company Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. primarily engages in the research, development, manufacturing, and sales of pharmaceutical products [1] - The company operates through five segments: - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines - The medical devices and diagnostics segment manufactures and sells molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices - The healthcare services segment operates an integrated online and offline medical service platform - The pharmaceutical distribution and retail segment is involved in the wholesale and retail of pharmaceutical products - Other segments engage in various pharmaceutical-related businesses [1] - The company's products are mainly used in the treatment fields of oncology, immunology, and central nervous system disorders [1]

Core Viewpoint - Fosun Pharma, founded in 1994 in Shanghai, is a global healthcare industry group driven by innovation, with a focus on pharmaceutical, medical devices, diagnostics, and healthcare services [1] Group 1: Company Overview - The company operates directly in various sectors including pharmaceuticals, medical devices, diagnostics, and healthcare services [1] - Pharmaceuticals represent the core business of the company and play a significant role in brand development [1] Group 2: Brand Management - The company aims to enhance its brand architecture by considering diverse business characteristics, industry specificity, business synergy, and market brand recognition [1]

Core Insights - Ping An Good Doctor has become the first company in the medical health industry to receive national-level personal information protection certification from the Central Cyberspace Administration of China [1] - The certification aims to standardize personal information processing activities and enhance data security in the healthcare sector [1] Group 1: Certification and Standards - The personal information protection certification is a national standard certification system jointly promoted by the State Administration for Market Regulation and the National Cyberspace Administration since 2022 [1] - The company’s personal information protection capabilities have been confirmed to fully comply with the national standard GB/T35273-2020, indicating its leading position in personal information protection in China [1] Group 2: Future Commitment and Industry Impact - The company plans to continue prioritizing data security and personal information protection as medical insurance and commercial insurance gradually integrate and medical AI develops rapidly [1] - The company aims to enhance its ESG development philosophy, improve personal information protection mechanisms, and strengthen overall data security capabilities to provide high-quality, efficient, and reliable healthcare services [1]

Core Viewpoint - Ping An Good Doctor (1833.HK) has become the first company in the medical and health industry to obtain national-level personal information protection certification in China, highlighting its commitment to data security and privacy protection [2]. Group 1: Certification and Standards - The personal information protection certification is a national standard certification system jointly promoted by the State Administration for Market Regulation and the National Internet Information Office since 2022, aimed at regulating personal information processing activities and enhancing data security [2]. - The certification reflects the company's leading position in personal information protection, demonstrating its institutional framework, technical capabilities, and ongoing management standards [2]. Group 2: Industry Implications - The handling of medical health data involves sensitive personal privacy, and the legality and security of related information processing activities are crucial for public trust and industry reputation [2]. - As medical insurance and commercial insurance gradually integrate and medical AI develops rapidly, the company will continue to prioritize data security and personal information protection [2]. Group 3: ESG Commitment - The certification serves as a strong endorsement of the company's commitment to the ESG sustainable development philosophy, emphasizing "technology for good and a caring heart" [2]. - The company aims to enhance its personal information protection mechanisms and overall data security capabilities while providing high-quality, efficient, and reliable medical health and elderly care services [2].

Group 1 - The core announcement is that Fosun Pharma plans to spin off Fosun Antigen and list it on the Hong Kong Stock Exchange, with an initial offering size not exceeding 25% of the expanded total share capital post-issuance [1] - The proposed listing will target a global audience, including institutional investors, enterprises, and qualified domestic institutional investors, with a maximum of 15% over-allotment option granted to global coordinators or bookrunners [1] - Fosun Antigen operates independently within the group, focusing on vaccine research, production, and sales, utilizing various technological platforms [1] Group 2 - After the spin-off, Fosun Antigen will remain a subsidiary of the company, and its financial performance will still be reflected in the consolidated financial statements of the group [2] - There may be a short-term reduction in the net profit attributable to the company from Fosun Antigen, but long-term prospects indicate improved financing capabilities and enhanced operational scale and competitiveness [2] - The spin-off does not involve the issuance of new shares and will not affect the company's equity structure [2]

Core Viewpoint - Fosun Pharma plans to spin off its subsidiary, Fosun Antigen, and list it on the Hong Kong Stock Exchange, with an initial offering size not exceeding 25% of the expanded total share capital post-issuance [1][2] Group 1: Spin-off Details - The proposed listing will involve H-shares with a par value of RMB 1.00 per share [1] - The initial offering will include an overallotment option of up to 15% of the initial issuance size [1] - The global offering will target institutional investors, enterprises, and qualified domestic investors, including those from Hong Kong, Macau, Taiwan, and other foreign regions [1] Group 2: Business Overview - Fosun Pharma is a global healthcare group driven by innovation, operating in pharmaceuticals, medical devices, diagnostics, and healthcare services [1] - Fosun Antigen focuses on vaccine research, production, and sales, utilizing various technological platforms [1] Group 3: Financial Implications - Post-spin-off, Fosun Antigen will remain a subsidiary, and its financial performance will still be reflected in Fosun Pharma's consolidated financial statements [2] - Short-term net profit contributions from Fosun Antigen may decrease, but long-term financing capabilities and operational scale are expected to improve, enhancing overall competitiveness and brand recognition [2] - The spin-off will not involve the issuance of new shares and will not affect the company's equity structure [2]

Group 1 - The core point of the news is that Fosun Pharma plans to spin off its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., for a separate listing on the Hong Kong Stock Exchange [1] - The board of directors approved the proposal for the spin-off and listing on January 22, 2026 [1] - Fosun Antigen serves as the vaccine business platform for the group, focusing on research, production, and sales of vaccines using various technological platforms [1] Group 2 - After the proposed spin-off, Fosun Antigen will remain a subsidiary of the company, and its financial status and profitability will still be reflected in the consolidated financial statements of the group [2] - In the short term, the net profit (or loss) attributable to Fosun Antigen may decrease, but in the long term, its financing capabilities are expected to strengthen, enhancing operational scale, production, and R&D capabilities [2] - The spin-off is anticipated to improve the overall profitability and long-term value of the group by increasing the comprehensive competitiveness, brand recognition, and market influence of Fosun Antigen [2]

Core Insights - The "First Beijing Trademark Brand Festival" was held on January 16, where the "Beijing Key Trademark Protection Directory" for 2025 was officially released, highlighting brands with high recognition and market leadership [1][3] - Ping An Good Doctor and Ping An Housekeeper were both selected for the directory, reflecting their strong brand reputation and market credibility [1][3] Group 1: Ping An Good Doctor - Established in 2014, Ping An Good Doctor aims to create a new model of Health Maintenance Organization (HMO) with Chinese characteristics, leading high-quality development in the healthcare sector [4] - The company has built a global medical service network and a leading team of doctors, successfully listed on the Hong Kong Stock Exchange in 2018 [4] - It has developed a comprehensive service network covering various healthcare scenarios, supported by its AI-driven services, which have served over 10 million users with a daily consultation rate exceeding 300,000 and a satisfaction rate above 98% [4] Group 2: Ping An Housekeeper - Launched in 2022, Ping An Housekeeper focuses on the core needs of the elderly, providing a comprehensive home care solution throughout their life cycle [5] - The service includes three major plans: illness management, safety assistance, and elderly care, supported by a team of doctors and specialists [5] - The service has achieved significant recognition, including being the first home care service to receive a five-star rating from the China Quality Certification Center, and has expanded to cover 100 cities with nearly 240,000 clients served [5]

Core Viewpoint - The "First Beijing Trademark Brand Ceremony" highlighted the inclusion of "Ping An Good Doctor" and "Ping An Housekeeper" in the 2025 "Beijing Key Trademark Protection List," recognizing their brand value and market influence [1][2]. Group 1: Trademark Protection - The establishment of the "Beijing Key Trademark Protection List" aims to protect registered trademarks with high recognition and market leadership in Beijing [2]. - The evaluation process for the list is organized by the Beijing Trademark Association, utilizing a strict selection from an expert pool composed of industry associations and academic institutions [2]. Group 2: Ping An Good Doctor - "Ping An Good Doctor" has built significant market recognition since its establishment in 2014, becoming synonymous with professionalism and reliability in the healthcare sector [3]. - The company aims to create a unique Chinese-style Health Maintenance Organization (HMO) model, leveraging its extensive medical management experience and a global service network [4]. - The company has developed a comprehensive service network that includes "to line, to hospital, to home, and to enterprise" services, forming a closed-loop healthcare service system [4]. - The AI-driven services of "Ping An Good Doctor" have served over 10 million users, with daily consultations exceeding 300,000 and a satisfaction rate above 98% [4]. Group 3: Ping An Housekeeper - Launched in 2022, "Ping An Housekeeper" focuses on the core needs of the elderly, providing a comprehensive home care solution throughout their life cycle [5]. - The brand offers three major service plans: management during illness, safety assistance, and elder care, supported by a team of doctors and specialists [5]. - "Ping An Housekeeper" has established six group standards in the home care sector, becoming a significant reference for industry standardization [6]. - The service has achieved a 100% response rate for its "smart guardian" alerts and has covered 100 cities, serving nearly 240,000 clients [6].